{"id":830432,"date":"2025-03-27T07:07:47","date_gmt":"2025-03-27T11:07:47","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-reports-2024-financial-results-and-provides-clinical-corporate-updates\/"},"modified":"2025-03-27T07:07:47","modified_gmt":"2025-03-27T11:07:47","slug":"calcimedica-reports-2024-financial-results-and-provides-clinical-corporate-updates","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-reports-2024-financial-results-and-provides-clinical-corporate-updates\/","title":{"rendered":"CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Enrollment ongoing in Phase 2\u00a0KOURAGE trial of Auxora\u2122 in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025<\/i>\n <\/p>\n

\n Post-hoc analysis of subset of patients with AKI in the Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia showed a 62.7% relative reduction in mortality at day 30, which persisted through day 60, for patients treated with Auxora versus placebo<\/i>\n <\/p>\n

\n Cash position expected to fund operations into mid-2026<\/i>\n <\/p>\n

\n
\n LA JOLLA, Calif.<\/span>
\n <\/span>, March 27, 2025<\/span><\/span> \/PRNewswire\/ — CalciMedica Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the year ended December 31, 2024<\/span> and provided clinical and corporate updates.<\/p>\n

\n

\n
\n \"CalciMedica
\n <\/a>\n <\/p>\n<\/p><\/div>\n

“Enrollment in our Phase 2 KOURAGE trial is on track to deliver data around the end of 2025,” said Rachel Leheny<\/span>, Ph.D., Chief Executive Officer of CalciMedica. “Looking ahead to the KOURAGE readout, we are further encouraged by the promising readthrough from the data recently presented at the 30th<\/sup> International AKI & CRRT Conference, which show a 62.7% relative reduction in mortality in CARDEA patients with both kidney failure and respiratory failure, mirroring KOURAGE’s patient population. With the proceeds from our recent credit facility with Avenue Capital, we have ample runway to get through our KOURAGE data readout based on our current enrollment projections and engage with the FDA on the design of a Phase 3 program in acute pancreatitis with SIRS in the next few months.”<\/p>\n

\n Recent Clinical & Corporate Highlights:<\/b>\n <\/p>\n

\n
\n Clinical Updates & Anticipated Milestones<\/u>
\n <\/i>\n <\/p>\n

\n \u00a0 \u00a0 \u00a0Acute Kidney Injury (AKI) Program Update<\/i>\n <\/p>\n